MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Liquidia Corporation (NASDAQ: LQDA)*
Organization & Developments: Liquidia
Parents
Liquidia Corporation (NASDAQ: LQDA)*
Children
*Combining a deep understanding of particle-based drug development with breakthrough small molecule and biological therapeutics
*Liquidia is engineering vaccines and therapies that have the potential to dramatically improve the quality of human life.
*Liquidia Technologies Founder Receives Prestigious $500,000 Lemelson-MIT Prize
*Liquidia Technologies is developing highly precise particle-based vaccines and therapeutics for the prevention and treatment of human disease.
*Liquidia: New Product and Business Developments/Partnerships
*Utilizing a novel platform known as PRINT® technology
2009: Liquidia Founder Receives Prestigious NIH Director's Pioneer Award
2011: Gates Foundation pumps $10M into NC nanotech company Liquidia
2011: Nanotechnology firm Liquidia partners with PATH on new pneumonia vaccine (2011)
2020: Liquidia Receives Complete Response Letter (CRL) from FDA for LIQ861 (treprostinil) Inhalation Powder for the Treatment of Pulmonary Arterial Hypertension Nasdaq:LQDA
2020: Looking Into Liquidia Technologies_seekingalpha.com
2021: Liquidia: If FDA Approves PAH Therapy Next Month, Share Price Uplift Isn't Guaranteed
2022: Liquidia: United Manages A Temporary Win_seekingalpha.com
2023: Liquidia Gains Edge In PAH Market Following Key Legal Victory_ seekingalpha.com
2024: Liquidia Corporation: A Complicated Tale
2024: Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
2024: Liquidia Misses Full Approval for Pulmonary Hypertension Drug as Competitor Retains Market Exclusivity
2024: Liquidia's Yutrepia Delay: The Clock Is Ticking On Financial Viability (Rating Downgrade)
2024: The Analyst Landscape: 11 Takes On Liquidia
2025: Liquidia Corporation's Long-Running Saga Is Coming To An End
2025: Liquidia: Competitor Insmed's Stunning PAH Data Arrives At Precisely The Wrong Time
Jumps
*Key People: Liquidia
Finance & Acquisitions: Liquidia